The Swan Song for Vytorin/Zetia Begins, in Earnest. . . .

or, Crestor’s “Jupiter” Study is a three bagger!

It’s very hard to imagine why anyone would, after today, pay for a three- to ten-times more expensive placebo, when 48 percent reductions in CV event risks are being achieved on statins (albeit a rather pricey, branded statin). In my estimation, plain old generic statins are sure to benefit from this data, as well. So, stick a fork in Vytorin/Zetia — that barbeque is over:

. . . .“Compared to those who received placebo, patients receiving the drug rosuvastatin also had a 48 percent reduction in stroke, a 46 percent reduction in the need for interventions to reopen blocked blood vessels and a 20 percent drop in all-cause mortality,” said Paul M. Ridker, M.D., lead author of the study and director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, Boston, Mass. . . .

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s